Re: From the NEJM: The FDA's New “Breakthrough Therapy” Designation
I believe you're wrong about TDm1, it has been approved and is now named Kadcyla. If we want more drugs approved more quickly by the FDA, we should be ready to pay for more FDA personnel.
__________________
|